Novartis Moves M&A Search to Early-Stage Drugs on Price Gain

Novartis Moves M&A Search to Early-Stage Drugs on Price Gain


Novartis AG said it will scout for medicines that are in earlier stages of development as acquisition price tags climb across the industry. "The price of some of these assets has increased to the point that we don't feel like we can create value for Novartis shareholders,'' Chief Executive Officer Joe Jimenez said on a conference call with reporters on Tuesday.



from Biotech News